Temple acquires London-based longevity medicine practice Longevous
3 min read
Funding Alert
September 1, 2026
Health‑tech firm Temple has acquired the London‑based longevity‑medicine practice Longevous for an undisclosed sum. The deal will bolster Temple’s clinical and scientific expertise as it readies its wearable health‑monitoring device for market.
Key Takeaways
- Health-tech firm Temple, founded by Eternal CEO Deepinder Goyal, has acquired London-based longevity-medicine practice Longevous for an undisclosed sum.
- The deal strengthens Temple’s clinical and scientific expertise ahead of launching its wearable health-monitoring device.
- Longevous co-founders Dr. Robert Mohr and Dr. Avi Roy will join Temple full-time as chief medical officer and head of science, respectively.
- The acquisition aims to help Temple translate wearable health data into clinically relevant insights.
Founded by Deepinder Goyal—co‑founder and CEO of Eternal—Temple focuses on longevity, preventive health, and continuous monitoring. Its forthcoming wearable, designed to sit near the temple, will capture physiological signals linked to overall health and wellbeing.
Longevous delivers evidence‑based longevity medicine, guiding clients toward improved long‑term health through monitoring, preventive care, lifestyle adjustments, and personalized medical advice.
As part of the acquisition, Longevous co‑founders Dr Robert Mohr and Dr Avi Roy will join Temple full‑time. Mohr will assume the role of chief medical officer, while Roy will become head of science; their teams will also transition to Temple.
Integrating seasoned physicians and scientists is crucial for Temple, because a wearable that gathers vast data must translate that information into accurate, clinically relevant insights. The acquisition provides Temple with Longevous’s clinical experience and scientific know‑how to validate its wearable technology—ensuring the device measures signals reliably and yields genuinely useful health guidance.
The move also gives Temple a direct foothold in the UK’s expanding longevity and preventive‑health sector. Longevous will continue operating under the Temple brand, with its founders maintaining personal responsibility for existing clients.
For Longevous, affiliation with Temple opens doors to greater technology, engineering resources, and capital. Its physicians and researchers can contribute to digital‑health product development while preserving their client‑focused work.
The transaction mirrors a broader shift toward preventive healthcare: consumers increasingly track sleep, activity, heart health, stress, nutrition, and other metrics that influence long‑term wellbeing, seeking insight before symptoms arise.
Nevertheless, longevity technology presents challenges. Health data is highly sensitive, requiring robust privacy, security, consent, and responsible‑use frameworks. Temple must also ensure its insights are medically sound, avoiding unnecessary anxiety or encouraging decisions without professional oversight.
Arriving ahead of Temple’s broader product launch, the acquisition underscores the importance of clinical credibility. While curiosity may draw early adopters, ultimate acceptance will hinge on accuracy, comfort, usefulness, battery life, price, and the quality of the insights delivered.
Temple’s long‑term vision lies in marrying medical expertise with cutting‑edge hardware and software. If it can produce a device that reliably captures health signals and converts them into actionable advice, it could secure a strong position in the emerging longevity market.
By acquiring Longevous, Temple gains a stronger scientific foundation as it advances toward commercialisation. The next milestone will be demonstrating that the technology delivers trustworthy, clinically meaningful, and genuinely helpful information to users.
